Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
1 other identifier
observational
29
1 country
1
Brief Summary
The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2011
CompletedFirst Submitted
Initial submission to the registry
October 24, 2011
CompletedFirst Posted
Study publicly available on registry
October 26, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2018
CompletedMarch 28, 2019
March 1, 2019
6.6 years
October 24, 2011
March 27, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
LPL Protein Expression
Determine the degree of LPL protein expression in CLL cells using a novel LPL antibody, correlate with IgHV mutation status, and compare this association with other prognostic markers
1 year
Secondary Outcomes (1)
Fatty acid acquisition and synthesis
1 year
Study Arms (1)
No treatment
No intervention. Each patient will have blood drawn at a standard of care venipuncture.
Eligibility Criteria
Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center with CLL
You may qualify if:
- Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
- Patients undergoing routine blood draws as part of their ongoing follow up for CLL
- years or older
- Ability to provide consent in English
- Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.
You may not qualify if:
- Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
- other hematologic malignancy or other disease process within the past 6 months are excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dartmouth-Hitchcock Medical Centerlead
- American Cancer Society, Inc.collaborator
Study Sites (1)
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
Biospecimen
10 cc of peripheral blood and Archived lymph node tissue or bone marrow samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Frederick Lansigan, MD
Dartmouth-Hitchcock Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Medicine
Study Record Dates
First Submitted
October 24, 2011
First Posted
October 26, 2011
Study Start
October 1, 2011
Primary Completion
May 1, 2018
Study Completion
May 1, 2018
Last Updated
March 28, 2019
Record last verified: 2019-03